Table 1.
Demographic details of study participants and eligible patients, not included in the study.
| Patient characteristic | Included; n (%) | Eligible, not included; n (%) | p-value (chi-squared) |
|---|---|---|---|
| 27 (100%) | 15 (100%) | – | |
| Gender | 0.25 | ||
| Male | 17 (63) | 12 (80) | |
| Female | 10 (37) | 3 (20) | |
| Age | |||
| ≤65 | 11 (41) | () | |
| >65 | 16 (59) | () | |
| Tumor site | 0.63 | ||
| Nasal cavity | 19 (70) | 11 (73) | |
| Maxillary sinus | 8 (30) | 3 (7) | |
| Sphenoid sinus | 0 | 1 (20) | |
| T-stage | 0.69 | ||
| 1 | 5 (18.5) | 4 (26.5) | |
| 2 | 8 (29.5) | 6 (40) | |
| 3 | 3 (11) | 1 (7) | |
| 4 | 11 (41) | 4 (26.5) | |
| Treatment | 0.39 | ||
| Combination of surgery and IMRT | 20 (74) | 9 (60) | |
| IMRT alone | 7 (26) | 6 (40) | |
| Histology | 0.53 | ||
| Squamous Cell Carcinoma | 16 (59) | 11 (73) | |
| Adenocarcinoma | 5 (19) | 1 (7) | |
| Other | 6 (22) | 3 (20) | |
| Prescribed radiation dose | 0.33 | ||
| 60 Gy | 10 (37) | 3 (20) | |
| 66 Gy | 12 (44) | 11 (73) | |
| ≥68 Gy | 5 (19) | 1 (7) | |
| Chemotherapy | 0.75 | ||
| No chemotherapy | 21 (78) | 11 (73) | |
| Concomitant cisplatin | 6 (22) | 2 (13.5) | |
| Other concomitant regimes | 0 | 2 (13.5) |